Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies

现代抗逆转录病毒疗法相关毒性、耐受性和合并症的药物基因组学和系统药理学方法

基本信息

  • 批准号:
    10453562
  • 负责人:
  • 金额:
    $ 82.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-10 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

ABSTRACT Antiretroviral therapy (ART) has resulted in people living with HIV (PLWH) now aging with prolonged survival, yet high rates of complications and comorbid conditions. This is due to a complex interplay between HIV infection, host genetics, and traditional risk factors leading to comorbidities. Understanding the role of genetic modification of drug responses to specific ART combinations through pharmacogenetic (PGx) evaluation could improve drug efficacy, mitigate ART-related side effects and reduce comorbidities. Discovering informative ART-PGx variants could not only help identify PLWH at risk for ART-associated adverse events and comorbidities, but also anticipate side effects of nascent ART combinations. However, despite lifelong need for ART, no comprehensive analysis of the role of genetic variation among PLWH in clinical care on combination ART regimens have been conducted to better understand the wide variety of adverse clinical outcomes they experience. We will use CNICS (Centers for AIDS Research Network of Integrated Clinical Systems), a large well-characterized prospective cohort of PLWH in care in the U.S with in-depth longitudinal clinical data including medications, health behaviors, laboratory test results, and validated and adjudicated diagnoses. In this largest genetic study in PLWH to date, we will characterize the genetic landscape of a variety of adverse side effects associated with ART regimens using existing genome-wide array data and newly generated next generation sequencing data from ethnically/racially diverse phenotypic extremes. We will also use the systems pharmacology approach to identify specific ART-induced pathways that are involved in the pathogenesis of adverse events using relevant cell model systems. We will test the hypothesis that the increased risk of adverse effects and comorbidities associated with ART can be explained, at least in part, by a burden of common and/or low frequency genetic variants that exacerbate ART effects. Aim 1: Conduct a genome-wide screening of variants that modify ART efficacy, including change in CD4 and viral load; ART tolerability, including renal and hepatic toxicity, and ART-associated adjudicated comorbidities in ~14,000 PLWH from the CNICS cohort. The significant findings will be validated in independent cohorts; Aim 2: Identify biological pathways and related key driver genes through which various ART regimens promote adverse events using a systems pharmacology approach and validate the findings in clinical cohorts, and Aim 3: Using novel technologies, determine individual PGx gene profiles associated with ART-induced diverse adverse clinical phenotypes by sequencing PLWH with the most severe toxicities, poor efficacy and tolerability, and adverse effects or comorbidities. The proposed studies promise to enhance our understanding of the biological mechanisms of ART response, helping reduce HIV-related complications. Identification of genetic modifiers of combination ART regimens is an important step towards risk stratification, prevention strategies and tailored treatment options for PLWH, ultimately helping develop a strong evidence base for personalized medicine.
摘要 抗逆转录病毒疗法(ART)导致艾滋病毒感染者(PLWH)现在衰老,生存期延长, 但并发症和合并症的发生率很高。这是由于艾滋病毒和艾滋病之间复杂的相互作用, 感染、宿主遗传学和导致合并症的传统风险因素。了解基因的作用 通过药物遗传学(PGx)评价, 改善药物功效、减轻ART相关副作用和减少合并症。发现信息 ART-PGx变异不仅有助于识别ART相关不良事件风险的PLWH, 合并症,但也预期新生ART组合的副作用。然而,尽管终身需要 ART,没有综合分析PLWH间遗传变异的作用,在临床护理上应联合应用 进行ART方案是为了更好地了解各种不良临床结果, 体验.我们将使用CNICS(艾滋病研究中心综合临床系统网络),一个大型的 美国PLWH治疗中的一个特征良好的前瞻性队列,具有深入的纵向临床数据 包括药物治疗、健康行为、实验室测试结果以及经验证和裁定的诊断。在 这项迄今为止在PLWH中进行的最大规模的遗传研究,我们将描述各种不利因素的遗传景观。 使用现有的全基因组阵列数据和新生成的下一个数据, 从人种/种族多样的极端表型中产生测序数据。我们还将使用 药理学方法,以确定参与发病机制的特定ART诱导途径 使用相关细胞模型系统的不良事件。我们将检验这样一个假设, 与ART相关的不良反应和合并症至少部分可以解释为 常见和/或低频率的遗传变异,加剧ART效应。目标1:进行全基因组 筛选改变ART功效的变体,包括CD 4和病毒载量的变化; ART耐受性, 包括肾脏和肝脏毒性,以及ART相关的裁定合并症,来自 CNICS队列。将在独立队列中验证重要发现;目标2:确定生物学 各种ART方案促进不良事件的途径和相关关键驱动基因, 系统药理学方法,并验证临床队列中的发现,目的3:使用新的 技术,确定与ART诱导的各种不良临床 通过测序PLWH表型,具有最严重的毒性、较差的疗效和耐受性以及不良反应。 影响或合并症。拟议中的研究有望增强我们对生物学的理解。 抗逆转录病毒治疗反应机制,帮助减少艾滋病毒相关并发症。基因修饰物的鉴定 联合抗逆转录病毒疗法是朝着风险分层、预防策略和量身定制的目标迈出的重要一步。 PLWH的治疗选择,最终帮助制定个性化医疗的强有力的证据基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Heidi M. Crane其他文献

Correction to: Genetic architecture of cardiometabolic risks in people living with HIV
对“HIV 感染者心脏代谢风险的遗传结构”的更正
  • DOI:
    10.1186/s12916-021-01976-9
  • 发表时间:
    2021-05-05
  • 期刊:
  • 影响因子:
    8.300
  • 作者:
    Haoxiang Cheng;Anshuman Sewda;Carla Marquez-Luna;Sierra R. White;Bridget M. Whitney;Jessica Williams-Nguyen;Robin M. Nance;Won Jun Lee;Mari M. Kitahata;Michael S. Saag;Amanda Willig;Joseph J. Eron;W. Christopher Mathews;Peter W. Hunt;Richard D. Moore;Allison Webel;Kenneth H. Mayer;Joseph A. Delaney;Paul K. Crane;Heidi M. Crane;Ke Hao;Inga Peter
  • 通讯作者:
    Inga Peter
Impact of Depression and HIV Symptoms on Glycemic Outcomes among Patients with HIV and Type 2 Diabetes: A Clinical Cohort Study
  • DOI:
    10.1007/s10461-025-04653-7
  • 发表时间:
    2025-02-17
  • 期刊:
  • 影响因子:
    2.400
  • 作者:
    Veronica Joyce Brady;Amanda L. Willig;Katerina A. Christopoulos;David J. Grelotti;George A. Yendewa;Conall O’Cleirigh;Richard D. Moore;Sonia Napravnik;Allison Webel;Heidi M. Crane;Michael S. Saag;Stephanie A Ruderman
  • 通讯作者:
    Stephanie A Ruderman
Domestic prevalence of substance use disorders in HIV care settings
  • DOI:
    10.1016/j.drugalcdep.2016.08.237
  • 发表时间:
    2017-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Bryan Hartzler;Dennis Donovan;Blair Beadnell;Heidi M. Crane;Joseph J. Eron;Elvin H. Geng;William C. Matthews;Kenneth H. Mayer;Richard D. Moore;Michael Mugavero;Sonia Napravnik;Benigno Rodriguez;Julia C. Dombrowski
  • 通讯作者:
    Julia C. Dombrowski
Barriers to accessing medications for opioid use disorder among rural individuals
农村个体获取阿片类药物使用障碍治疗药物的障碍
  • DOI:
    10.1016/j.drugpo.2025.104805
  • 发表时间:
    2025-06-01
  • 期刊:
  • 影响因子:
    4.400
  • 作者:
    Anna M. Morenz;Robin M. Nance;L. Sarah Mixson;Judith Feinberg;Gordon Smith;P. Todd Korthuis;Mai T. Pho;Wiley D. Jenkins;Peter D Friedmann;Thomas J. Stopka;Laura C. Fanucchi;William C. Miller;Vivian F. Go;Ryan Westergaard;David W. Seal;William A. Zule;Heidi M. Crane;Joseph A. Delaney;Judith I. Tsui
  • 通讯作者:
    Judith I. Tsui
Rural houselessness among people who use drugs in the United States: Results from the National Rural Opioid Initiative
  • DOI:
    10.1016/j.drugalcdep.2024.112498
  • 发表时间:
    2025-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    April M. Ballard;Zora Kesich;Heidi M. Crane;Judith Feinberg;Peter D. Friedmann;Vivian F. Go;Wiley D. Jenkins;P.Todd Korthuis;William C. Miller;Mai T. Pho;David W. Seal;Gordon S. Smith;Thomas J. Stopka;Ryan P. Westergaard;William A. Zule;April M. Young;Hannah LF Cooper
  • 通讯作者:
    Hannah LF Cooper

Heidi M. Crane的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Heidi M. Crane', 18)}}的其他基金

Understanding Health Inequities at the Intersection of the HIV and substance use epidemics across racial/ethnic and other underserved populations
了解不同种族/族裔和其他服务不足人群中艾滋病毒和药物滥用流行病交汇处的健康不平等
  • 批准号:
    10738418
  • 财政年份:
    2023
  • 资助金额:
    $ 82.36万
  • 项目类别:
Alcohol Research Consortium in HIV: Epidemiology Research Arm
艾滋病毒酒精研究联盟:流行病学研究部门
  • 批准号:
    10304374
  • 财政年份:
    2021
  • 资助金额:
    $ 82.36万
  • 项目类别:
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)
阿片类药物使用研究和治疗计划的农村合并症和艾滋病毒后果(农村队列)
  • 批准号:
    9762537
  • 财政年份:
    2019
  • 资助金额:
    $ 82.36万
  • 项目类别:
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)
阿片类药物使用研究和治疗计划的农村合并症和艾滋病毒后果(农村队列)
  • 批准号:
    10369630
  • 财政年份:
    2019
  • 资助金额:
    $ 82.36万
  • 项目类别:
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)
阿片类药物使用研究和治疗计划的农村合并症和艾滋病毒后果(农村队列)
  • 批准号:
    9882992
  • 财政年份:
    2019
  • 资助金额:
    $ 82.36万
  • 项目类别:
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies
现代抗逆转录病毒疗法相关毒性、耐受性和合并症的药物基因组学和系统药理学方法
  • 批准号:
    10668985
  • 财政年份:
    2019
  • 资助金额:
    $ 82.36万
  • 项目类别:
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)
阿片类药物使用研究和治疗计划的农村合并症和艾滋病毒后果(农村队列)
  • 批准号:
    10600982
  • 财政年份:
    2019
  • 资助金额:
    $ 82.36万
  • 项目类别:
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies
现代抗逆转录病毒疗法相关毒性、耐受性和合并症的药物基因组学和系统药理学方法
  • 批准号:
    10198979
  • 财政年份:
    2019
  • 资助金额:
    $ 82.36万
  • 项目类别:
Implementation and Evaluation of psPRO: Person-specific Patient-Reported Outcome Assessments for Patients in HIV Care living with Multiple Chronic Conditions
psPRO 的实施和评估:对患有多种慢性病的 HIV 护理患者进行个体化患者报告的结果评估
  • 批准号:
    10002227
  • 财政年份:
    2019
  • 资助金额:
    $ 82.36万
  • 项目类别:
Implementation and Evaluation of psPRO: Person-specific Patient-Reported Outcome Assessments for Patients in HIV Care living with Multiple Chronic Conditions
psPRO 的实施和评估:对患有多种慢性病的 HIV 护理患者进行个体化患者报告的结果评估
  • 批准号:
    9789484
  • 财政年份:
    2019
  • 资助金额:
    $ 82.36万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 82.36万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 82.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 82.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 82.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 82.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 82.36万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 82.36万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 82.36万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 82.36万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 82.36万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了